Back to Results

NewGenIvf Group Ltd (NIVF)

NewGenIvf Group Ltd is a Bangkok-based healthcare company listed on NASDAQ under the ticker NIVF. Through its clinic network, the company provides assisted reproductive services for couples and individuals seeking fertility treatment in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Its service portfolio includes in vitro fertilization (IVF), ICSI, embryo culture, hormonal and infectious disease testing, chromosome screening, hysteroscopy, sperm analysis, sperm sorting, washing and freezing, and egg freezing. The company also supports IVF-related surrogacy arrangements with ancillary care services such as regular health checks, vitamins, supplements, and medicines for surrogate mothers. In addition, it offers value-added support including nutrition guidance, psychological counselling, acupuncture, and translation services. Founded in 2010, NewGenIvf Group operates as an investment holding company within the healthcare providers and services segment.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-NIVF
$1.29
4.2% Upside
Fair
$42.36 3,316.1% Upside
—
Bargain
Weak
—
—
—
0.0%
September 1, 2026
0.4x
0.2x
0.9x
4.399 M
7.466 M
56.4%
98.9%
6.4
—
-112.0%
Valuation • Fair Value

NewGenIvf Group Ltd (NASDAQ-NIVF) Fair Value by Valuation Model

Compare the primary fair value estimate for NewGenIvf Group Ltd (NASDAQ-NIVF) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.29

Estimated upside of 4.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$32.65

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.29

Comparable-company valuation reference.

Analyst Price Target

$42.36 3,316.1% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for NewGenIvf Group Ltd (NASDAQ-NIVF) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for NewGenIvf Group Ltd (NASDAQ-NIVF)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

4.726 M

Current operating scale indicator.

Revenue Forecast

65.1 M

Forward revenue estimate.

EBITDA

-10.538 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review NewGenIvf Group Ltd (NASDAQ-NIVF) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for NewGenIvf Group Ltd (NASDAQ-NIVF)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

33.16

Higher caution zone on this screen.

Altman Z-Score

6.4

Relatively strong balance-sheet zone.

FCF / Net Income

-112.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for NewGenIvf Group Ltd (NASDAQ-NIVF). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for NewGenIvf Group Ltd (NASDAQ-NIVF)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 1, 2026

Days to Earnings

42

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for NewGenIvf Group Ltd (NASDAQ-NIVF), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

NewGenIvf Group Ltd (NASDAQ-NIVF) Stock Forecast & Technical Outlook

Review NewGenIvf Group Ltd (NASDAQ-NIVF) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for NewGenIvf Group Ltd (NASDAQ-NIVF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for NewGenIvf Group Ltd (NASDAQ-NIVF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for NewGenIvf Group Ltd (NASDAQ-NIVF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for NewGenIvf Group Ltd (NASDAQ-NIVF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for NewGenIvf Group Ltd (NASDAQ-NIVF) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for NewGenIvf Group Ltd (NASDAQ-NIVF)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for NewGenIvf Group Ltd (NASDAQ-NIVF) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

NewGenIvf Group Ltd (NASDAQ-NIVF) Stock FAQ

Quick answers about NewGenIvf Group Ltd (NASDAQ-NIVF) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.29
Estimated upside 4.2%
Valuation Rating
Undervalued
Estimated upside of 4.2%
Analyst Target
$42.36 3,316.1% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for NewGenIvf Group Ltd (NASDAQ-NIVF) is $1.29. This implies an estimated upside of 4.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.2% versus the current market price.

The available analyst price target for NewGenIvf Group Ltd (NASDAQ-NIVF) is $42.36 3,316.1% Upside.

The current financial health read for NewGenIvf Group Ltd (NASDAQ-NIVF) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for NewGenIvf Group Ltd (NASDAQ-NIVF) is September 1, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for NewGenIvf Group Ltd (NASDAQ-NIVF) is 0.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for NewGenIvf Group Ltd is 4.399 M.

The current enterprise value listed for NewGenIvf Group Ltd is 7.466 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for NewGenIvf Group Ltd is NASDAQ-NIVF, and the stock is listed on NASDAQ.

NewGenIvf Group Ltd (NASDAQ-NIVF) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for NewGenIvf Group Ltd is 56.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for NewGenIvf Group Ltd is 98.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NASDAQ View more

Guardant Health Inc (GH) Guardant Health Inc (GH)
Brightspring Health Services Inc (BTSG) Brightspring Health Services Inc (BTSG)
Brightspring Health Services Inc Unit (BTSGU) Brightspring Health Services Inc Unit (BTSGU)
The Ensign Group Inc (ENSG) The Ensign Group Inc (ENSG)
Henry Schein Inc (HSIC) Henry Schein Inc (HSIC)
Healthequity Inc (HQY) Healthequity Inc (HQY)
RadNet Inc (RDNT) RadNet Inc (RDNT)
Lifestance Health Group Inc (LFST) Lifestance Health Group Inc (LFST)
Alignment Healthcare LLC (ALHC) Alignment Healthcare LLC (ALHC)
Option Care Health Inc (OPCH) Option Care Health Inc (OPCH)
Privia Health Group Inc (PRVA) Privia Health Group Inc (PRVA)
Acadia Healthcare Company Inc (ACHC) Acadia Healthcare Company Inc (ACHC)
CorVel Corp (CRVL) CorVel Corp (CRVL)
Progyny Inc (PGNY) Progyny Inc (PGNY)
Clover Health Investments Corp (CLOV) Clover Health Investments Corp (CLOV)
Aveanna Healthcare Holdings Inc (AVAH) Aveanna Healthcare Holdings Inc (AVAH)
Surgery Partners Inc (SGRY) Surgery Partners Inc (SGRY)
Addus HomeCare Corporation (ADUS) Addus HomeCare Corporation (ADUS)
Astrana Health Inc (ASTH) Astrana Health Inc (ASTH)
NeoGenomics Inc (NEO) NeoGenomics Inc (NEO)
GeneDx Holdings Corp (WGS) GeneDx Holdings Corp (WGS)
InnovAge Holding Corp (INNV) InnovAge Holding Corp (INNV)
Adapthealth Corp (AHCO) Adapthealth Corp (AHCO)
Pennant Group Inc (PNTG) Pennant Group Inc (PNTG)